Who Benefits From 5 Years of Extended Endocrine Therapy?

MammaPrint genomic testing suggests that only patients with low-risk, not ultra-low-risk or high-risk, breast cancer benefit from 5 years of extended endocrine therapy.

Related Keywords

Orlando ,Florida ,United States ,Terry Mamounas ,University Of San Francisco ,Orlando Health Cancer Institute ,Department Of Surgery ,San Francisco ,San Antonio Breast Cancer Symposium ,Medscape Medical ,Breast Cancer Index ,Breast Cancer ,Alignant Breast Neoplasm ,Endocrine Therapy ,Cancer ,Alignant Neoplasia ,Arcinoma ,Genomics ,Genomic Medicine ,Edicine Genomic ,Metastasis ,Breast ,Tamoxifen ,Elective Estrogen Receptor Modulator Serm ,Aromatase Inhibitor ,Exemestane ,Tumor ,Distant Metastasis ,Istant Metastases ,Biomarker ,Iological Marker ,Disease Recurrence ,Hands ,Receptors ,Surgery ,